BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
BeiGene’s BTKi is approved in more than 65 markets globally ... | May 30, 2023
Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BeiGene’s BTKi is approved in more than 65 markets globally ... | May 30, 2023
Highlights from early- and late-stage pipeline include -- combination data for cornerstone therapies BRUKINSA and tislelizumab -- early results for OX40 agonist BGB-A445 and BCL-2 inhibitor... | May 25, 2023
BeiGene , a global biotechnology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences: TD Cowen 4th Annual Oncology Innovation Summit... | May 24, 2023
StockNews.com assumed coverage on shares of BeiGene (NASDAQ:BGNE – Get Rating) in a research report report published on Thursday morning. The brokerage issued a hold rating on the stock. Several other equities research analysts have also weighed in on BGNE. Cowen lifted their price target on BeiGene from $213.00 to $262.00 and gave the company […]
StockNews.com assumed coverage on shares of BeiGene (NASDAQ:BGNE – Get Rating) in a report published on Thursday. The firm issued a hold rating on the stock. Several other brokerages have also issued reports on BGNE. Guggenheim reiterated a buy rating and issued a $350.00 price target on shares of BeiGene in a research note on […]